**FOI Ref: 6489**

**Category(ies): Clinical - Drugs**

**Subject: Use of Biologic Medications to Treat Dermatological Conditions**

**Date Received: 11/07/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am analysing the usage of new biologic medications for the treatment of dermatological conditions. I would greatly appreciate if you could answer the following question. |
| How many patients were treated in June 2022 (or latest available month) by the dermatology department with the following drugs:* Abrocitinib (Cibinqo)
* Baricitinib (Olumiant)
* Bimekizumab (Bimzelx)
* Brodalumab (Kyntheum)
* Dupilumab (Dupixent)
* Ixekizumab (Taltz)
* Risankizumab (Skyrizi)
* Guselkumab (Tremfya)
* Secukinumab (Cosentyx)
* Tildrakizumab (Ilumetri)
* Tralokinumab (Adtralza)
* Upadacitinib (Rinvoq)
* Ustekinumab (Stelara)
 | * 0
* 1
* 0
* 2
* 29
* 3
* 6
* 22
* 19
* 0
* 0
* 0
* 11
 |